GENE ONLINE|News &
Opinion
Blog

2018-10-11| Asia-PacificPolicy

Live Report – 2018 BioJapan: Witness Japan’s biotechnology industry development policy and the innovation of pharmaceutical industry

by GeneOnline
Share To

2018 BioJapan was launched on October 10th at Pacifico Yokohama National Convention Hall. GeneOnline listed some of the highlights shared by two key opinion leaders in medicine.

Concentrate on the development of biotechnology in order to solve the issues on society.

Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI), mentioned that Japanese government has outlined “Society 5.0” project in “Japan Revitalization Strategy”, in order to integrate the relevant units and implement the effective resource allocation and structural reform.

Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI)
Mazakazu Tokura, the president of SUMITOMO CHEMICAL , also a member of Council for Science, Technology and Innovation (CSTI)

Regarding to this, Japanese government’s appeal is to let the policy and technology development become closer, more organized and flexible, and commit to expanding the market and accelerating the development of computer science and biotechnology.

The technology integration is real data and domain technology for biotechnology, which combines big data in various fields with cutting edge technologies such as genetic technology, AIoT, bioinformatics, etc. As well as connects to the country that has sound system on biomedical, such as the United States, United Kingdom, Germany, etc., in order to become the well-known country in global biotechnology industry.

The future of drug development and innovation

George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA), introduced that JPMA consists of 71 research-based pharmaceuticals in Japan and is a research-oriented voluntary organization.

George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA)
George Nakayama, president of Japan Pharmaceutical Manufacturers Association (JPMA)

He mentioned that Japan should work hard in three directions to catch up with the United States. To begin with, the establishment of the infrastructure, including the establishment of a health care database, such as genome and clinical diagnostic information, and the construction of ID facilities. Then, in order to provide sufficient funds for basic scientific research, the government and industry should cooperate to create profits. Finally, the government should establish an ecosystem without borders, especially establish a close relationship with the United States actively.

“Stay tuned to GeneOnline for more special articles on BioJapan 2018”

medtex最新-e1538653867506

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Major U.S. Organization BIO Severs Ties With Member WuXi AppTec Amid U.S. Government’s Security Concerns
2024-03-15
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top